Genus plc (LON:GNS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,810.28 ($23.53) and traded as high as GBX 1,994 ($25.92). Genus shares last traded at GBX 1,992 ($25.90), with a volume of 87,838 shares changing hands.
Wall Street Analysts Forecast Growth
Separately, Shore Capital reaffirmed a “buy” rating on shares of Genus in a research report on Wednesday, December 11th.
Check Out Our Latest Stock Analysis on GNS
Genus Stock Performance
Genus (LON:GNS – Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported GBX 39.80 ($0.52) EPS for the quarter. Genus had a return on equity of 1.41% and a net margin of 1.18%. On average, research analysts forecast that Genus plc will post 70.9644323 EPS for the current year.
Insider Activity at Genus
In other Genus news, insider Jorgen Kokke sold 19,967 shares of Genus stock in a transaction dated Friday, February 28th. The stock was sold at an average price of GBX 1,731 ($22.50), for a total transaction of £345,628.77 ($449,335.37). 0.75% of the stock is currently owned by company insiders.
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.
Featured Articles
- Five stocks we like better than Genus
- How to Calculate Stock Profit
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Alphabet’s Officially In A Bear Market—Time To Buy?
- 3 Tickers Leading a Meme Stock Revival
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.